Based on preliminary unaudited information and subject to the year-end accounting close and audit, Anika expects total revenue for the fourth quarter ended December 31, 2012 in the range of $22.0 million to $23.0 million, compared with $18.4 million in the fourth quarter of 2011. For full-year 2012, total revenue is expected to be between $70.0 million and $71.6 million, compared with $64.8 million a year earlier.
Anika expects to equal or exceed its previously announced guidance of $0.74 net income per diluted share for full-year 2012. This includes, as announced on December 28, 2012, a pre-tax charge of approximately $2.5 million related to the closure of the company’s tissue engineering facility in Abano Terme, Italy.
“Anika delivered solid revenue growth in the fourth quarter of 2012, concluding an excellent year from both operational and financial perspectives,” said Sherwood. “Our top-line performance continues to be driven by strong worldwide demand for our flagship orthobiologics product Orthovisc®. On the bottom line, improvements in our operating efficiency, coupled with growing revenue, have enabled us to drive continued growth in income from operations and strong cash flow.”
Sorry to see Kevin go.
I liked Kevin.I thought he did a good job.
ANIKA will deliver a record fourth qtr.
Look for eps in excess of 0.40/share.
Waiting to hear whats next with respect to MONOVISC.
Since Mitek owns distribution rights I expect them to reimburse ANIKA for R&D ( new clinical trials) if we go that route.
I've waited too long with ANIK and had to sell most of my position back in December. I thought this had potential but the wait was too long, over 4 years. I think I made the mistake of falling in love with it. All that I sold went into UNXL which again I may have fallen in love with. Please do your due diligence in this stock as it is a company involved in a disruptive technology. They just signed an unknown client (believed to be Dell) to a $15 million dollar deal. They have been in talks with TI so that tells you something. Do your research quickly as this stock is about to take off from $16 to $25 when they announce their next agreement with another big time player (i.e. Apple , Texas Instruments or another big time player). This is the ground floor.
Yep, the old CEO gave a solid performance, even when the numbers weren't!
As for monovisc, I expect it to be buried now. After all, the docs make more money with orthovisc, which might be one reason it is taking mkt share. An added therapeutic ingredient to whatever is in monovisc is a better idea... just as long as they have a customer first this time!